FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan
Acurx has received FDA guidance from a July 2026 Type C meeting on ibezapolstat's Phase 3 clinical program, including the potential for a single-Phase 3-trial registration plan and a trial design supporting both treatment and reduction of r